rs1800544 — ADRA2A ADRA2A Promoter -1291C>G

The Adrenergic Brake on Fat Storage and Insulin Release

Your nervous system uses adrenaline as a metabolic switch — flooding tissues with it during stress to mobilize energy. In two critical tissues, this signal travels through the alpha-2A adrenergic receptor¹¹ alpha-2A adrenergic receptor
A G-protein-coupled receptor that mediates inhibitory responses to adrenaline and noradrenaline: pancreatic beta cells, where it suppresses insulin secretion, and fat cells, where it applies the brakes on lipolysis (fat breakdown). A variant 1,291 base pairs upstream of the ADRA2A gene (-1291C>G) alters how much of this receptor protein a cell makes — and that difference has measurable consequences for how your body handles metabolic stress and responds to certain medications.

The Mechanism

The ADRA2A gene encodes the alpha-2A adrenergic receptor, which is expressed at high levels in pancreatic beta cells and adipocytes. When adrenaline activates this receptor, it inhibits cAMP production, suppressing both glucose-stimulated insulin secretion and incretin-amplified insulin release via the cAMP/TRPM2 signalling axis²² cAMP/TRPM2 signalling axis
Transient receptor potential melastatin 2 channels couple alpha-2A receptor activation to reduced membrane excitability in beta cells. In adipose tissue, the same inhibitory signal reduces lipolytic flux, favouring fat retention.

The -1291 position lies in the promoter region — the DNA segment that governs how much RNA (and ultimately protein) the gene produces. Small et al. 2006³³ Small et al. 2006
Small KM et al. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. PNAS, 2006 demonstrated that noncoding haplotypes across the ADRA2A gene produce up to 5-fold differences in receptor transcript and surface protein levels across cell lines. Higher receptor density means a stronger adrenergic brake on insulin secretion and a tighter hold on stored fat.

The Evidence

The clearest clinical signal for rs1800544 comes from drug-induced weight gain. Sickert et al. 2009⁴⁴ Sickert et al. 2009
Sickert L et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics, 2009 tracked 60 European-Americans on clozapine or olanzapine for 6–14 weeks. C allele carriers (CC + CG) gained 3.73 ± 4.13 kg, compared with just 0.23 ± 2.92 kg for GG homozygotes (p=0.013). The same directionality appeared with the antidepressant mirtazapine: Lee et al. 2009⁵⁵ Lee et al. 2009
Lee HY et al. Association of the adrenergic alpha 2a receptor -1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Research, 2009 found the CC genotype gained more weight after 8 weeks of mirtazapine treatment in 314 MDD patients (p=0.052).

Conversely, when patients were switched from weight-inducing antipsychotics to metabolically neutral alternatives, the GG genotype showed the greatest benefit: Roffeei et al. 2014⁶⁶ Roffeei et al. 2014
Roffeei SN et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human Psychopharmacology, 2014 found GG carriers lost 1.04 ± 1.63 kg/m² BMI vs only 0.32 ± 1.41 kg/m² for C allele carriers when switching to aripiprazole or ziprasidone (p=0.013).

On metabolic physiology, Rosmond et al. 2002⁷⁷ Rosmond et al. 2002
Rosmond R et al. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. Journal of Internal Medicine, 2002 studied 284 Swedish men and found that heterozygous C/G carriers had impaired dexamethasone suppression (higher post-dex cortisol, p=0.009) and elevated fasting glucose compared with GG homozygotes (p=0.017). The mechanism proposed: altered receptor density destabilises sympathetic–hypothalamic–pituitary–adrenal axis tone, raising ambient cortisol and blunting insulin sensitivity. Separately, Kochetova et al. 2015⁸⁸ Kochetova et al. 2015
Kochetova OV et al. Genetic association of ADRA2A and ADRB3 genes with metabolic syndrome among the Tatars. Genetika, 2015 found GG and GC genotypes were associated with higher fasting insulin and elevated HOMA-IR in Tatar women with metabolic syndrome — a finding that conflicts somewhat with the antipsychotic weight-gain literature and illustrates that the direction of effect likely depends on the specific metabolic context and concomitant treatments.

Practical Actions

The most actionable signal from rs1800544 relates to medications that engage the adrenergic system or carry known weight-gain liabilities. C allele carriers starting clozapine, olanzapine, or mirtazapine face substantially elevated risk of rapid weight accumulation. Pre-emptive monitoring of weight and waist circumference, and selecting metabolically neutral alternatives where clinically appropriate, represents the most evidence-grounded response.

Separately, the G allele is associated with better methylphenidate response in ADHD (Hain et al. 2022⁹⁹ Hain et al. 2022
Hain DT et al. Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in ADHD. Biological Psychiatry Global Open Science, 2022; OR 3.08, 95% CI 1.71–5.56, p=0.0002 across 9 studies). This is a pharmacogenomic signal with potential utility in paediatric ADHD prescribing decisions.

Interactions

The ADRA2A rs553668 and rs521674 promoter variants tag partially overlapping haplotypes within the same regulatory region, and their combined effects on receptor expression may be additive. The 5-fold expression range reported by Small et al. encompasses multi-SNP haplotypes, not single variants in isolation; users carrying multiple ADRA2A promoter variants may have amplified effects on adrenergic tone.

In the context of obesity genetics, ADRA2A interacts functionally with the beta-3 adrenergic receptor (ADRB3, rs4994) — both regulate sympathetic control of adipose tissue lipolysis from opposing directions. Combined carriership of ADRA2A and ADRB3 risk variants has been explored in metabolic syndrome cohorts.